Browse drugs

… for Gem/NabP. Recorded grade ≥3 toxicities appeared lower with NALIRIFOX, although cross-regimen safety comparisons were limited by retr…

…ain characteristics of 2359 PWH enrolled in the Bictegravir and Dolutegravir SCOLTA cohortsAbstract P20 Table 2Reasons for 568 discontinuati…

… thrombolytic administered within 4.5 hours of stroke symptoms. Tenecteplase (TNK) is FDA-approved for STEMI, but its off-label use for AIS …

…duals at borderline or intermediate risk of ASCVD.16 Similarly, FIB-4 may serve an analogous role in nephrology by identifying patien…

…therapy with SGLT2i and GLP-1 RA relative to those who received SGLT2i monotherapy was significantly lower in patients with HF and T2D…

… brief counselling and SMS-text based cessation support whereas cannabis use is monitored but not treated. Biochemical verification (thr…

…iated with a numerically lower risk of worsening HF compared to gabapentin users (HR 0.71, 95% CI 0.09-5.43) (figure 1). Overall, the dire…

…8Ga]Ga-PSMA are prognostic correlates with therapy response for cabozantinib, a VEGF inhibitor, for ccRCC.72 In RCC, ccRCC shows the highest…

…ltants, 3N Endovascular, Basecampv Vascular SAS, Borvo Medical, CerebrovaKP, Code Zero, Collavidence, Contego, FreeOx Biotech, Hyperion Sur…

…ant (FNET) and palonosetron (PAL). Prior to administration, the Akynzeo concentrate (20 mL vial) is diluted with 30 mL 0.9% sodium chlo…

…, endoscopic improvement (Obe-50-PBO Δ: 17.8%, p<0.0001), HEMI (Obe-50-PBO Δ: 11.1%, p=0.0005), and symptomatic remission (Obe-50-PBO Δ: 2…

… (≤12 [IV: GUS=43%, PBO=21%; SC: GUS=52%, PBO=24%] and >12 [IV: GUS=53% vs PBO=16%; SC: GUS=62% vs PBO=18%]), baseline CRP (≤3mg/L …